Compare ELSE & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELSE | IMNN |
|---|---|---|
| Founded | 1968 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.0M | 12.9M |
| IPO Year | N/A | 1985 |
| Metric | ELSE | IMNN |
|---|---|---|
| Price | $4.40 | $4.06 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $182.61 |
| AVG Volume (30 Days) | 2.9K | ★ 33.4K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $9,787,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $38.90 | ★ N/A |
| Revenue Growth | ★ 5.36 | N/A |
| 52 Week Low | $3.65 | $3.56 |
| 52 Week High | $5.50 | $41.22 |
| Indicator | ELSE | IMNN |
|---|---|---|
| Relative Strength Index (RSI) | 36.67 | 48.74 |
| Support Level | $4.48 | $3.83 |
| Resistance Level | $4.70 | $4.35 |
| Average True Range (ATR) | 0.06 | 0.20 |
| MACD | -0.01 | 0.06 |
| Stochastic Oscillator | 0.00 | 58.54 |
Electro-Sensors Inc manufactures and sells industrial production monitoring and process control systems. It manufactures a complete line of monitoring and control systems for a wide range of industrial machine applications. The systems measure machine production and operation rates, as well as regulate the speed of related machines in production processes. Its products include motor drive control, position monitors, sensor targets, signal conditioners, speed sensors, speed switches, tachometers, temperature sensors, vibration monitors, etc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).